Price Comparison
ARA-290
recovery
24 of 24 vendors
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Ascension Peptides 8.5/10 COA ✓Ships: USVisa · ACH bank draft Verification & shipping8.5/10 COA ✓Ships: USVisa · ACH bank draft | $29.00 | $29.00Checked apr 16, 2026 | Apr 16, 2026 | Buy ARA-290 from Ascension Peptides |
| Purus Peptides 8.5/10 COA ✓Ships: USCredit/debit card Verification & shipping8.5/10 COA ✓Ships: USCredit/debit card | $32.00 | $32.00Checked aug 6, 2026 | Aug 6, 2026 | Buy ARA-290 from Purus Peptides |
| Amino Club 10/10 COA ✓Ships: US + internationalVisa · American Express Verification & shipping10/10 COA ✓Ships: US + internationalVisa · American Express | $32.49 | $32.49Checked aug 7, 2026 | Aug 7, 2026 | Buy ARA-290 from Amino Club |
| Alpha Peptides 8/10 COA ✓Ships: USCredit/debit card Verification & shipping8/10 COA ✓Ships: USCredit/debit card | $36.00 | $36.00Checked jul 31, 2026 | Jul 31, 2026 | Buy ARA-290 from Alpha Peptides |
| Chameleon Peptides 10/10 COA ✓Ships: USCredit/debit card · Apple Pay Verification & shipping10/10 COA ✓Ships: USCredit/debit card · Apple Pay | $36.9010mg package | $36.90Checked jul 31, 2026 | Jul 31, 2026 | Buy ARA-290 from Chameleon Peptides |
| MS Peptides 8/10 COA ✓Ships: US + internationalCredit/debit card · ACH Verification & shipping8/10 COA ✓Ships: US + internationalCredit/debit card · ACH | $38.69 | $38.69Checked aug 19, 2026 | Aug 19, 2026 | Buy ARA-290 from MS Peptides |
Research details
ARA-290 — research data
Half-life~20 minutes after a 4 mg SC dose in a published human pharmacokinetic analysis.
Regulatory statusNot FDA-approved (Phase 2 trials)
NCAA D1Banned
Overview
About ARA-290
Mechanism of action
Investigational non-erythropoietic EPO-derived peptide designed to activate the proposed innate repair receptor (IRR); early human studies examined anti-inflammatory and tissue-repair signaling.
Safety profile
Short human trials reported generally good tolerability, but long-term and uncommon risks remain unknown. One diabetes-trial participant stopped after worsening borderline renal insufficiency. · Small, short Phase 2 trials reported generally good tolerability; long-term and uncommon risks remain unknown
Related pages
More on ARA-290
Learn More
ARA-290 Guide
See the exact 2 mg IV and 1, 4, and 8 mg SC regimens studied in humans, plus the evidence for nerve repair.
Read full guide · 9 min read →